Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gatifloxacin

FDA-approved product (solution/drops, ophthalmic), marketed as Gatifloxacin, Zymar, Zymaxid.

Registered studies
39
Lab records
43
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Gatifloxacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial conjunctivitis
  • Bacterial disease
  • Eye infection
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fluoroquinolones
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA16; WHO ATC S01AE06

Repurposing investigation

Gatifloxacin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae90.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis98.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

39registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 3 of 3 lab records
  • E. coli: measured active in 5 of 5 lab records
  • K. pneumoniae: measured active in 14 of 14 lab records
  • M. tuberculosis: measured active in 21 of 21 lab records
Open Gatifloxacin in ChEMBL Registered studies below
Show the 43 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gatifloxacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Analysis of Postoperative Ocular Surface Changes and Intervention Effect After PPV in MGD Dry Eye Patients

    NCT05771194 · start 2021-02-01

    Registered record
    Registry ID
    NCT05771194
    Conditions
    Meibomian Gland Dysfunction of Unspecified Eye, Unspecified Eyelid
    Interventions
    Routine preoperative and postoperative anti-infection therapy; artificial tear therapy; Cleaning, hot compresses and massage of the meibomian gland
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-02-01
    Completion
    2022-07-02
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeibomian Gland Dysfunction of Unspecified Eye, Unspecified Eyelid
    InterventionRoutine preoperative and postoperative anti-infection therapy; artificial tear therapy; Cleaning, hot compresses and massage of the meibomian gland
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.

    NCT03696342 · start 2018-10-01

    Registered record
    Registry ID
    NCT03696342
    Conditions
    Conjunctivitis, Bacterial
    Interventions
    Pazufloxacin; Zymar
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2018-10-01
    Completion
    2020-03-24
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConjunctivitis, Bacterial
    InterventionPazufloxacin; Zymar
    PhasePhase 3
    Registry statusTerminated

  • Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis

    NCT03625739 · start 2018-07-01

    Registered record
    Registry ID
    NCT03625739
    Conditions
    Tuberculosis
    Interventions
    anti-tuberculosis drug
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-07-01
    Completion
    2026-12-31
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionanti-tuberculosis drug
    PhaseNot recorded
    Registry statusRecruiting

  • Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen

    NCT03578276 · start 2018-06-22

    Registered record
    Registry ID
    NCT03578276
    Conditions
    Cataract
    Interventions
    Pred-Gati-Brom; Prednisolone acetate 1% ophthalmic suspension; Gatifloxacin Ophthalmic; Bromfenac 0.075% Oph Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-06-22
    Completion
    2019-12-04
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract
    InterventionPred-Gati-Brom; Prednisolone acetate 1% ophthalmic suspension; Gatifloxacin Ophthalmic; Bromfenac 0.075% Oph Solution
    PhasePhase 4
    Registry statusCompleted

  • A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

    NCT03479736 · start 2017-11-20

    Registered record
    Registry ID
    NCT03479736
    Conditions
    Retinal Detachment; Achilles Tendon; Aneurysm, Dissecting
    Interventions
    Oral Fluoroquinolones (FQ); Other Antibiotics; Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-11-20
    Completion
    2018-06-04
    Enrolment
    117,911

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinal Detachment; Achilles Tendon; Aneurysm, Dissecting
    InterventionOral Fluoroquinolones (FQ); Other Antibiotics; Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
    PhaseNot recorded
    Registry statusCompleted

  • The Individualized M(X) Drug-resistant TB Treatment Strategy Study

    NCT03237182 · start 2017-06-14

    Registered record
    Registry ID
    NCT03237182
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Individualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-06-14
    Completion
    2022-12-19
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionIndividualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    PhasePhase 4
    Registry statusTerminated

  • Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis

    NCT02717871 · start 2016-03

    Registered record
    Registry ID
    NCT02717871
    Conditions
    Keratitis; Infectious Disease (Manifestation)
    Interventions
    PACK-CXL; Cefazolin in combination with either tobramycin or gentamicin; Cycloplegic agents (cyclopentolate 1% eye drops); Fluoroquinolones (Besifloxacin; ciprofloxacin; gatifloxacin; levofloxacin; moxifloxacin; ofloxacin ); Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-03
    Completion
    2020-10
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeratitis; Infectious Disease (Manifestation)
    InterventionPACK-CXL; Cefazolin in combination with either tobramycin or gentamicin; Cycloplegic agents (cyclopentolate 1% eye drops); Fluoroquinolones (Besifloxacin +6 more
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)

    NCT02980523 · start 2015-03

    Registered record
    Registry ID
    NCT02980523
    Conditions
    Bacterial Conjunctivitis
    Interventions
    PRO-157; Vigamox; Zymar®; Lagricel Ofteno®
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-03
    Completion
    2017-05
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Conjunctivitis
    InterventionPRO-157; Vigamox; Zymar®; Lagricel Ofteno®
    PhasePhase 2
    Registry statusCompleted

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated

  • A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

    NCT01928693 · start 2013-07

    Registered record
    Registry ID
    NCT01928693
    Conditions
    Corneal Ulcers
    Interventions
    Besivance 0.6% Ophthalmic Suspension; Zymaxid 0.5% Ophthalmic Solution; Vigamox 0.5% Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-07
    Completion
    2014-05
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Ulcers
    InterventionBesivance 0.6% Ophthalmic Suspension; Zymaxid 0.5% Ophthalmic Solution; Vigamox 0.5% Ophthalmic Solution
    PhasePhase 2
    Registry statusTerminated

  • Research of the Application of Triple Antibiotic Paste in Primary Teeth With Pericpical Periodontitis

    NCT02196740 · start 2013-06

    Registered record
    Registry ID
    NCT02196740
    Conditions
    Periapical Diseases
    Interventions
    Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste; creosote
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2013-06
    Completion
    2015-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeriapical Diseases
    InterventionMetronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste; creosote
    PhaseNot applicable
    Registry statusUnknown

  • Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever

    NCT01421693 · start 2011-09

    Registered record
    Registry ID
    NCT01421693
    Conditions
    Enteric Fever; Typhoid Fever
    Interventions
    Ceftriaxone; Gatifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-09
    Completion
    2015-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnteric Fever; Typhoid Fever
    InterventionCeftriaxone; Gatifloxacin
    PhasePhase 4
    Registry statusCompleted

  • Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

    NCT01330355 · start 2011-05

    Registered record
    Registry ID
    NCT01330355
    Conditions
    Bacterial Conjunctivitis
    Interventions
    Besivance; Gatifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-05
    Completion
    2013-10
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Conjunctivitis
    InterventionBesivance; Gatifloxacin
    PhasePhase 3
    Registry statusTerminated

  • Corneal Cross-linking and Refractive Surface Ablation in Patients With Asymmetric Corneas

    NCT02943967 · start 2010-01

    Registered record
    Registry ID
    NCT02943967
    Conditions
    Surgical Procedure, Unspecified
    Interventions
    CXL + PRK group; PRK group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-01
    Completion
    2014-01
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurgical Procedure, Unspecified
    InterventionCXL + PRK group; PRK group
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision

    NCT00892918 · start 2009-06

    Registered record
    Registry ID
    NCT00892918
    Conditions
    Primary Pterygium
    Interventions
    Moxifloxacin ophthalmic solution 0.5%; Gatifloxacin ophthalmic solution 0.3%
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2009-06
    Completion
    2010-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Pterygium
    InterventionMoxifloxacin ophthalmic solution 0.5%; Gatifloxacin ophthalmic solution 0.3%
    PhaseNot applicable
    Registry statusUnknown